The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Bracketed generic inactivation of rodent retroviruses by low pH treatment for monoclonal antibodies and recombinant proteins
Abstract
Viral safety is a predominant concern for monoclonal antibodies (mAbs) and other recombinant proteins (RPs) with pharmaceutical applications. Certain commercial purification modules, such as nanofiltration and low‐pH inactivation, have been observed to reliably clear greater than 4 log 10 of large enveloped viruses, including endogenous retrovirus. The concept of “bracketed generic clearance” has been proposed for these steps if it could be prospectively demonstrated that viral log 10 reduction value (LRV) is not impacted by operating parameters that can vary, within a reasonable range, between commercial processes. In the case of low‐pH inactivation, a common step in mAb purification processes employed after protein A affinity chromatography, these parameters would include pH, time and temperature of incubation, the content of salts, protein concentration, aggregates, impurities, model protein p I, and buffer composition. In this report, we define bracketed generic clearance conditions, using a prospectively defined bracket/matrix approach, where low‐pH inactivation consistently achieves ≥4.6 log 10 clearance of xenotropic murine leukemia virus (X‐MLV), a model for rodent endogenous retrovirus. The mechanism of retrovirus inactivation by low‐pH treatment was also investigated. © 2003 Wiley Periodicals, Inc. Biotechnol Bioeng 82: 321–329, 2003.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure of influenza haemagglutinin at the pH of membrane fusion
Bullough, P. A., Hughson, F. M., Skehel, J. J., & Wiley, D. C. (1994) · Nature · doi:10.1038/371037a0 · Cited by 1,564
Skehel, J. J., Bayley, P. M., Brown, E. B., Martin, S. R., Waterfield, M. D., White, J. M., Wilson, I. A., & Wiley, D. C. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.4.968 · Cited by 726
Cited by
Downstream processing of monoclonal antibodies—Application of platform approaches
Shukla, A. A., Hubbard, B., Tressel, T., Guhan, S., & Low, D. (2007) · Journal of Chromatography B · doi:10.1016/j.jchromb.2006.09.026 · Cited by 876
Recovery and purification process development for monoclonal antibody production
Liu, H. F., Ma, J., Winter, C., & Bayer, R. (2010) · mAbs · doi:10.4161/mabs.2.5.12645 · Cited by 561
Future of antibody purification
Low, D., O’Leary, R., & Pujar, N. S. (2007) · Journal of Chromatography B · doi:10.1016/j.jchromb.2006.10.033 · Cited by 472
Very Large Scale Monoclonal Antibody Purification: The Case for Conventional Unit Operations
Kelley, B. (2007) · Biotechnology Progress · doi:10.1021/bp070117s · Cited by 337
Viral clearance for biopharmaceutical downstream processes
Shukla, A. A., & Aranha, H. (2015) · Pharmaceutical Bioprocessing · doi:10.4155/pbp.14.62 · Cited by 63
Metadata
- Authors
- Brorson, K., Krejci, S., Lee, K., Hamilton, E., Stein, K., & Xu, Y.
- Venue
- Biotechnology and Bioengineering
- Publisher
- Wiley
- Published
- 2003-02-21
- Volume
- 82
- Issue
- 3
- Pages
- 321-329
- ISSN
- 0006-3592 (ISSN-L)
- 1097-0290
- OpenAlex
- W2014545180
- Cited by
- 159
- References
- 2
- FWCI
- 0.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bracketed generic inactivation of rodent retroviruses by low pH treatment for monoclonal antibodies and recombinant proteins. https://app.cochat.ai/papers/10.1002/bit.10574
- The paper
- Brorson, K., Krejci, S., Lee, K., Hamilton, E., Stein, K., & Xu, Y. (2003). Bracketed generic inactivation of rodent retroviruses by low pH treatment for monoclonal antibodies and recombinant proteins. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.10574
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.